Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pascaline Berthet

Showing results (31-40 of 74) with videos related to

Pageof 8
Sort By:
Human Mutation|May 18, 2026
<i>MLH1</i> Constitutional Epimutation Screening Requires Highly Sensitive Assays to Identify Lynch Syndrome Patients With Very Low Mosaic Methylation LevelCédric Facon, Catherine Vermaut, Lucie Delattre, et al.
JAMA|June 7, 2011
Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndromeValérie Bonadona, Bernard Bonaïti, Sylviane Olschwang, et al.
Breast Cancer Research : BCR|July 6, 2012
Variation in breast cancer risk associated with factors related to pregnancies according to truncating mutation location, in the French National BRCA1 and BRCA2 mutations carrier cohort (GENEPSO)Julie Lecarpentier, Catherine Noguès, Emmanuelle Mouret-Fourme, et al.
Familial Cancer|November 15, 2011
Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trialPascal Pujol, Christine Lasset, Pascaline Berthet, et al.
Breast Cancer Research and Treatment|November 14, 2015
Mutation analysis of PALB2 gene in French breast cancer familiesFrancesca Damiola, Inès Schultz, Laure Barjhoux, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 24, 2015
Breast Cancer Risk Associated with Estrogen Exposure and Truncating Mutation Location in BRCA1/2 CarriersJulie Lecarpentier, Catherine Noguès, Emmanuelle Mouret-Fourme, et al.
Human Mutation|December 9, 2021
Novel germline MET pathogenic variants in French patients with papillary renal cell carcinomas type IMolka Sebai, David Tulasne, Sandrine M Caputo, et al.
Carcinogenesis|October 6, 2017
Telomere length, ATM mutation status and cancer risk in Ataxia-Telangiectasia familiesAnne-Laure Renault, Noura Mebirouk, Eve Cavaciuti, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 13, 2003
BRCA1 wild-type allele modifies risk of ovarian cancer in carriers of BRCA1 germ-line mutationsSophie M Ginolhac, Sophie Gad, Marilys Corbex, et al.
International Journal of Cancer|May 19, 2005
Breast cancer risk in BRCA1 and BRCA2 mutation carriers and polyglutamine repeat length in the AIB1 geneDavid J Hughes, Sophie M Ginolhac, Isabelle Coupier, et al.
Pageof 8

Showing results (31-40 of 74) with videos related to

Sort By:
Pageof 8
Human Mutation|May 18, 2026
<i>MLH1</i> Constitutional Epimutation Screening Requires Highly Sensitive Assays to Identify Lynch Syndrome Patients With Very Low Mosaic Methylation LevelCédric Facon, Catherine Vermaut, Lucie Delattre, et al.
JAMA|June 7, 2011
Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndromeValérie Bonadona, Bernard Bonaïti, Sylviane Olschwang, et al.
Breast Cancer Research : BCR|July 6, 2012
Variation in breast cancer risk associated with factors related to pregnancies according to truncating mutation location, in the French National BRCA1 and BRCA2 mutations carrier cohort (GENEPSO)Julie Lecarpentier, Catherine Noguès, Emmanuelle Mouret-Fourme, et al.
Familial Cancer|November 15, 2011
Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trialPascal Pujol, Christine Lasset, Pascaline Berthet, et al.
Breast Cancer Research and Treatment|November 14, 2015
Mutation analysis of PALB2 gene in French breast cancer familiesFrancesca Damiola, Inès Schultz, Laure Barjhoux, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 24, 2015
Breast Cancer Risk Associated with Estrogen Exposure and Truncating Mutation Location in BRCA1/2 CarriersJulie Lecarpentier, Catherine Noguès, Emmanuelle Mouret-Fourme, et al.
Human Mutation|December 9, 2021
Novel germline MET pathogenic variants in French patients with papillary renal cell carcinomas type IMolka Sebai, David Tulasne, Sandrine M Caputo, et al.
Carcinogenesis|October 6, 2017
Telomere length, ATM mutation status and cancer risk in Ataxia-Telangiectasia familiesAnne-Laure Renault, Noura Mebirouk, Eve Cavaciuti, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 13, 2003
BRCA1 wild-type allele modifies risk of ovarian cancer in carriers of BRCA1 germ-line mutationsSophie M Ginolhac, Sophie Gad, Marilys Corbex, et al.
International Journal of Cancer|May 19, 2005
Breast cancer risk in BRCA1 and BRCA2 mutation carriers and polyglutamine repeat length in the AIB1 geneDavid J Hughes, Sophie M Ginolhac, Isabelle Coupier, et al.
Pageof 8